3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Genitourinary
3
Conditions
Carcinoma, Non-Small-Cell Lung
57
Breast Neoplasms
35
Neoplasms
32
Parkinson Disease 4, Autosomal Dominant Lewy Body
26
Multiple Myeloma
24
Leukemia, Myeloid, Acute
21
Recurrence
19
Neoplasm Metastasis
17
Colorectal Neoplasms
17
Ovarian Neoplasms
15
Lymphoma, Non-Hodgkin
15
Carcinoma, Renal Cell
15
Melanoma
14
Leukemia, Lymphocytic, Chronic, B-Cell
14
Leukemia
13
Precursor Cell Lymphoblastic Leukemia-Lymphoma
12
Lymphoma, Follicular
12
Urinary Bladder Neoplasms
11
Myelodysplastic Syndromes
11
Lung Neoplasms
11
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
10
Hematologic Neoplasms
10
Carcinoma, Hepatocellular
10
Stomach Neoplasms
9
Prostatic Neoplasms
9
Lymphoma, Mantle-Cell
9
Lymphoma, Large B-Cell, Diffuse
9
Lymphoma
9
Adenocarcinoma
9
Thyroid Neoplasms
8
Interventions
enfortumab vedotin
2
pembrolizumab
1
avelumab
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Interventional
×
Has announcements
×
Urologic Neoplasms
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA
NCT03219333
2024-08-27
EV-201
Astellas Pharma Inc
Phase 2
Completed
219 enrolled
32 charts
2 FDA
NCT02603432
2024-03-27
JAVELIN Bladder 100
Pfizer
Phase 3
Completed
700 enrolled
35 charts
1 FDA